Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
Authors
Keywords
HIV vaccines, Antibodies, Enzyme-linked immunoassays, Immune response, Antigens, Antibody response, Booster doses, Vaccination and immunization
Journal
PLOS MEDICINE
Volume 18, Issue 10, Pages e1003813
Publisher
Public Library of Science (PLoS)
Online
2021-10-30
DOI
10.1371/journal.pmed.1003813
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A model for establishment, maintenance and reactivation of the immune response after vaccination against Ebola virus
- (2020) Irene Balelli et al. JOURNAL OF THEORETICAL BIOLOGY
- Ebola virus disease
- (2019) Denis Malvy et al. LANCET
- Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Uganda and Tanzania
- (2019) Zacchaeus Anywaine et al. JOURNAL OF INFECTIOUS DISEASES
- Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Nairobi, Kenya
- (2019) Gaudensia Mutua et al. JOURNAL OF INFECTIOUS DISEASES
- Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults
- (2019) Scott A Halperin et al. JOURNAL OF INFECTIOUS DISEASES
- Dynamics of the humoral immune response to a prime-boost Ebola vaccine: quantification and sources of variation
- (2019) Chloé Pasin et al. JOURNAL OF VIROLOGY
- Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination
- (2018) Lise Gross et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay
- (2018) James Logue et al. JOURNAL OF VIROLOGICAL METHODS
- Outbreak of Ebola virus disease in the Democratic Republic of the Congo, April–May, 2018: an epidemiological study
- (2018) Ahmadou Barry et al. LANCET
- OUP accepted manuscript
- (2018) TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
- Prevention of Ebola virus disease through vaccination: where we are in 2018
- (2018) Yves Lévy et al. LANCET
- A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates
- (2018) Benoit Callendret et al. PLoS One
- Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)
- (2017) Ana Maria Henao-Restrepo et al. LANCET
- Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines
- (2016) Iain D. Milligan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates
- (2013) A. Marzi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started